A elogenous leukemia cells was detected in a cell lysate and the conditioned medium of the differentiation-resistant myelogenous leukemia M 1 cells. The purified differentiation inhibitory factor had a relative molecular mass of approximately 16 to 17 kD and its amino acid sequence determined from cyanogen bromide fragments was identical with that of nm23 proteins, which are involved in tumor metastasis regulation and contain nucleoside diphosphate (NDP) kinase (EC 2.7.4.6) enzyme activity.' Authentic nm23 proteins and a mutant protein that was deficient in NDP kinase activity also inhibited the differentiation of human and mouse myelogenous leukemia cells, suggesting that the differentiation inhibitory activity is independent of NDP kinase There are at least two isotypes of human nm23 genes, namely nm23-HI and nm23-H2, which show 88% amino acid sequence homology4.' and locate on the same region of chromosome 17q21 in It is necessary to analyze expression of each gene product, since both isomers can effectively inhibit the differentiation of leukemia cells3 Postel et a19 reported that nm23-H2 is a transcription factor (PuF) and that one of its targets is the c-myc gene. Overexpression of c-myc gene also inhibits the differentiation of human and mouse leukemia cells.L0-12 Expression of the nm23 genes has been examined in several types of human cancer. However, these findings cannot be generalized because of contradictory results. 13 The nm23 transcripts have been detected in some leukemia cells. Recently, DR-nm23, the third nm23 type, was identified by differential screening cDNA clones preferentially expressed in CML blast crisis (CML-BC) ~e l 1 s . l~ It could be of great interest to study the role of these nm23 genes in abnormal growth and differentiation of leukemia cells. However, until now, very few studies have focused on the roles of nm23 in human hematopoietic malignancies. l5 Differentiation-resistant M 1 cells have higher leukemogenicity than the parent differentiation-sensitive cells16 and possess apparent differences in responsiveness to various regulatory molecules." These resistant cells produce the differentiation inhibitory factor nm23.".'* Therefore, in the present study we examined the expression of nm23-HI, -H2, and c-myc genes in human myelogenous elevated nm23-HI and -H2 mRNA levels. On the other hand, the elevated levels of c-mycexpression in AML-MI were less evident. An analysis of correlation between nm23 expression and clinicopathological parameters showed that resistance to initial chemotherapy is associated with increased nm23-Hl mRNA levels and that a high initial white blood cell count is associated with increased nm23-HZ mRNA levels. Elevated nm23-Hl mRNA levels were associated with significantly reduced the overall survival of AML, especially of AML-M5 patients. The present results indicate that nm23- leukemias. We showed that the nm23-HI and -H2 genes are overexpressed in AML, especially in AML-MS and that the levels of nm23-HI gene expression correlate with a poor prognosis in AML, especially in AML-MS.
MATERIALS AND METHODS
Clinical samples. Bone marrow (BM) and peripheral blood (PB) samples from 47 patients, including 42 with newly diagnosed acute myelogenous leukemia (AML) and 5 with newly diagnosed chronic myelogenous leukemia at chronic phase (CML-CP), were obtained with their informed consent at onset, before chemotherapy. AML was classified according to the criteria devised by the French-American-British (FAB) Committee. AML patients were treated with cytosine arabinoside (or behenoyl cytosine arabinoside), daunombicin, and with or without prednisolone andor 6-mercaptopurine, and AML-M3 patients were consecutively treated with all-trans retinoic acid for remission induction therapy.'y~20 Treated patients were judged to have achieved complete remission (CR) when BM aspirates showed tri-lineage regeneration with less than 5% blasts by morphology and immunocytochemistry, in the presence of a normal blood count that persisted for at least 1 month. Patients who died of toxic complication (infection or bleeding) before the time of expected marrow recovery were not evaluated. All other patients were considered nonresponsive (NR To purify normal lymphocytes and monocytes, normal PB mononuclear cells (PBMNC) were suspended in medium (1 X IO7 nucleated cells/mL) and cultured for 2 hours at 37°C in a humidified atmosphere of 5% C 0 2 in air. Lymphocytes were obtained as a nonadherent cell population, and monocytes were obtained from the adherent cell layer after washing eight times with RPMI-1640 medium. To purify normal granulocytes, whole PB cells were separated on a cushion of Mono-Poly Resolving Medium (Flow Laboratories, North Ryde, Australia). Total RNA was extracted as described by Chomczynski and Sacchi, using guanidium thiocyanate.2' Synthetic DNA probes specific for nm23-HI, nm23-H2, c-myc, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were labeled by the 5'-end labeling procedure. Total RNA samples (10 pg of each) were electrophoresed in formaldehyde-1 % agarose gels. Northern blots were prepared on nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) and fixed by baking for 2 hours at 80°C. Blots were preincubated for 2 to 4 hours at 42°C in prehybridization buffer (50% formamide, 6x SSC [0.9 mol/L NaCl and 0.09 mol/L sodium citrate], 5X Denhardt's solution (0. I % each of bovine serum albumin, Ficoll400, and polyvinylpyrrolidone), 0.5% sodium dodecyl sulfate [SDS], 0.01 mol& EDTA, pH 8.0,0. 1 mg/mL herring sperm DNA) and then incubated for 12 to 16 hours at the same temperature in hybridization buffer (prehybridization buffer with 10% dextran sulfate) containing the end-labeled probes. Blots were washed three times (20 minutes each) at 50°C in 2X SSC, 0.1% SDS, 0.2% sodium pyrophosphate, and then at 50°C in 0.1 X SSC, 0.1% SDS, and then they were exposed to BAS-I11 imaging plates (Fuji Film Co, Ltd, Tokyo, Japan) at room temperature for 1 to 12 hours. Amounts of individual mRNAs were quantified using a Fuji Bio-Image Analyzer BAS2000 (Fuji Film Co, Ltd).
Quantitative RT-PCR was performed using a GeneAmp RNA PCR kit (TaKaRa, Tokyo, Japan). The oligonucleotides used in PCR amplification were as follows: sense strand, 5'-ATGGCCAACTGTGAGCGTACC-3'; antisense strand, 5'-CATGTAT'TTCACCAGGCCGGC-3' for nm23-HI; sense strand, 5'-ATGGCCAACCTGGAGCGCACC-3'; antisense strand, 5'-TCCCCACGAATGGTGCCTGGC-3' for nm23-H2; sense strand, 5'-GTCCTCGGATTCTCTGCTCT-3'; antisense strand, 5'-GACTCTGACACTGTCCAACTT-3' for c-myc; sense strand, 5'-ACATCGCTCAGACACCATGG-3'; antisense strand, 5'-GTAGTTGAGGTCAATGAAG-3' for GAPDH. Based on the sequence information around the intron-exon junctions of each gene, the primers were designed to sandwich one intron and thus, specifically detect "A.
The RNA (0.2 pg) was revene transcribed to synthesize cDNA using random nonamers at 42"C, then amplified by means of PCR using specific primers (4 pmol) and 0. comprised 35 cycles for nm23-HI and 25 for nm23-H2, c-myc, and GAPDH, with denaturing at 95°C for 1 minute, annealing at 60°C for 1 minute, and extension at 72°C for 0.5 minute. The reaction was performed in a GeneAmp PCR system 9600 (Perkin Elmer, Norwalk, CT). The PCR products were then subjected to 6% polyacrylamide gel electrophoresis, and the radioactivity level in the dried gel was evaluated by means of autoradiography using BAS2000. The linearity of the quantitation of RT-PCR products of nm23-HI, nm23-H2, c-myc, and GAPDH was determined using various amounts of total RNA obtained from HEL cells. Under these conditions, the amount of PCR products Northern blot analysis.
Reverse transcriptase-polymerase chain reaction (RT-PCR).
labeled by incorporated [CU-'~P]~CTP linearly increased until 0.5 pg of total RNA (Fig 1) . Similar results were obtained from Northem hybridization and from RT-PCR (Fig 2) . To confirm that RT-PCR could mstinguish nm23-HI mRNA from nm23-HZ "A, we exposed the respective products to BglII (GIBCO-BRL, Gaithersburg, MD) and separated the resulting DNA fragments by electrophoresis on a 2% agarose gel. The nm23-HI PCR product, which contains a BglIl recognition site (AGATCT), was digested into two fragments (135 and 69 bp), but that of nm23-H2, whch does not contain the AGATCT sequence, remained intact (data not shown).
Statistical analysis. Statistical comparisons between groups were performed by means of Student's t-test, and P < .05 indicated a significant difference. Survival curves of patients were prepared by the Kaplan-Meier method, and statistical analysis of the difference between the survival curves was undertaken using the generalized Wilcoxon's and log-rank tests.
RESULTS
Expression of nm23-H1, -H2 and c-myc genes in AML. To normalize the differences in RNA loading for RT-PCR and in RNA degradation in individual samples, the values of the nm23-H1, -H2, and c-myc gene expression were divided by that of the GAPDH gene for comparison with the values in erythroleukemia HEL cells defined as 100 (the expression index).
To provide a baseline for comparison, nm23-H1, -H2, and c-myc expression was analyzed by quantitative RT-PCR in normal blood cells (Fig 3) . These normal cells expressed much less nm23-HI than HEL cells, and various levels of nm23-H2 and c-myc expression. The levels of nm23-HI, -H2, and c-myc mRNA in CML-CP cells were similar to the average levels in normal blood cells ( Table 1) . A summary of the statistical data in AML is given in Table 1 Fig 4) . The expression of the nm23-H2 gene in all the AML and AML-M5 cells was also statistically higher than that of normal blood cells ( P < .005 and < .0005, respectively). There was no significant difference in the c-myc gene expression between leukemic and normal cells (Table 1 ). There was no statistical correlation between any two of nm23-HI, -H2, and c-myc expression in the AML tested in this study. The AML-M2 cells expressed less nm23-HI, -H2, and c-myc genes than the other subtype of AML cells. The nm23-HI expression in AML-M2 leukemia cells with t(8;21) was lower than that of AML-M2 cells without t(8;21) ( P < .01) (data not shown).
These results indicated that the expression of nm23-Hl and -H2 but not c-myc in AML, especially in AML-MS, is significantly higher than that in normal blood cells.
Relationship between nm23 expression and clinical data. We determined the correlation between the expression of nm23-HI and -H2 and age, sex, white blood cell (WBC) counts, lactate dehydrogenase (LDH), chromosomal aberration, and response to initial therapy (Table 2) . Good response to initial therapy was inversely correlated with nm23-HI ( P use = .024), but not with nm23-H2 expression (P = .193). A total of 35 presentation samples were evaluable in terms of the response to treatment. Ten patients failed to achieve remission after the initial chemotherapy. The drug-resistant AML samples had increased nm23-HI expression (nm23-HI index = 70 2 49) compared with those from the 28 AML patients who achieved CR (the index = 42 2 36). This difference was statistically significant ( P = .024). On the other hand, nm23-H2 expression was not correlated with the response to the initial therapy, but higher expression was correlated with high WBC counts (>50 X IO9& P = .004) ( Table 2 ). The expressions of nm23-Hl and -H2 in AML-M2 leukemia cells with t(8;21) and of nm23-Hl in AML-M3 leukemia with t(15;17) show a tendency to decrease compared with that of the other AMLs without these chromosomal aberrations, although there were few patients ( Table 2) .
The hematologic and clinical features, as well as the outcome of 7 AML patients with a high nm23-HI index (> 100) are shown in Table 3 . The 4 patients had WBC counts >50 X 109/L, but those in patients with high nm23-HI index (>loo) (n = 7) were not statistically different from those with a low index (n = 32) ( P = .7933) (data not shown). Cytogenetic analysis of the AML cells with levels of nm23-HI expression over 100 showed a normal karyotype in 5 patients and that two had chromosomal aberrations (Table 3 ). The results suggested that the high expression of nm23-HI mRNA is not apparently associated with chromosomal aberration. There was a significant difference in overall survival curves between those 6 (no. 34 was excepted to receive BM transplantation) AML patients with a high nm23-HI index (>loo) and other AMLs (Fig 5A, P = ,0064 , generalized Wilcoxon test; .01 < P <
.025, log-rank test). Five of seven patients with a high nm23-HI index (> 100) are AML-M5, which are treated with same protocol and followed during a long time. Therefore, we examined the relationship between the level of nm23-HI gene expression and the overall survival of AML-M5 patients (Fig 5B) . The cutoff point of the nm23-HI index was selected as 100. AML-M5 patients with levels of nm23-HI gene expression below 100 had significantly higher rates of overall survival (6 patients, P = .015, generalized Wilcoxon test; .01 < P < .025, log-rank test) than those (4 patients) with levels over 100. RT-PCR analysis P < .001. The overall survival of the AML-M5 patients with a high (>loo) or low (<loo) nm23-H2 index was not statistically different (P = ,6384, data not shown), even when the cutoff points were varied, although the level of nm23-H2 expression in M5 cells was statistically higher than that of normal blood or other AML cells (P = .0039, Table I ).
These results showed that the levels of nm23-HI gene expression represent a new prognostic factor for AML, at least for AML-MS. t P < .05. * P < .01.
DISCUSSION
The nm23 gene was originally identified by the differential hybridization of a cDNA library with total RNA extracted from low and high metastatic melanoma cell lines2* The human nm23 genes localized to chromosome 17q21.6. ' Its expression was inversely correlated with the tumor metastatic potential of experimental rodent cells and with some human tumors.*' Transfection with nm23 cDNA reduced metastatic potential in vivo and the ability of the cells to migrate in response to cytokines in Reduced nm23 expression levels are correlated with increased metastatic potential and aggressive disease in human breast?' hepatocellular" ovarian,*' and gastric carcinoma" and in melanoma." However, the opposite trend has been identified in neuroblastoma and pancreatic ~arcinoma.'~,~'.~~ In other tumor types, including colorectal, thyroid, and lung carcinomas, nm23 expression does not correlate with disease progression.I3 These results suggest a functional difference of nm23 gene expression in several human tumor types. 13 In this study using RT-PCR, we determined the expression of nm23-HI and nm23-H2 mRNA in AML. The results showed that (1) both nm23-HI and nm23-H2 mRNA are highly expressed in AML ( Table 1) ; (2) nm23-HI mRNA abundance is correlated with the response to initial therapy and poor prognosis and that nm23-H2 mRNA abundance correlates with high WBC counts (Table 2) ; and (3) elevated nm23-HI mRNA levels were associated with significantly reduced overall survival of AML, especially of AML-M5 patients. Although the nm23-H2 gene product is identical to the c-myc transcription factor PuF," the expression of c-myc was not associated with that of nm23-H2 expression in AML. Transfection with the nm23 gene of melanoma K-1735 TK and breast carcinoma MDA-MB435 cells decreases the response to transforming growth factor-p (TGF-p).w,25 Differentiation-resistant M1 cells are resistant to not only differentiation-inducing cytokines but also to growth suppressive cytokines such as TGF-0. The differentiation-resistant cells gained more progressive potential, which was not suppressed by negative regulators. The role of nm23 expression on the malignant growth of leukemia cells remains to be clarified. A novel cDNA DR-nm23 is differentially expressed in a CML blast-crisis cDNA library, which has high sequence similarity to nm23, inhibits granulocyte differentiation, and induces apoptosis in 32Dc13 myeloid cells.I4 Our results showed that the expression levels of nm23-Hl and -H2 in AhIL, but not in CML-CP, were significantly higher than those in normal blood cells (Table 1) . We are currently investi- gating the expression of nm23-HI and -H2 in CML-BC and that of DR-nm23 in AML.
Elevated nm23 mRNA levels are significantly associated in neuroblastoma, with reductions in overall patient sur~i v a l .~* Here we found that there is a significant association of increased nm23-HI mRNA levels with a poor prognosis in AML-MS. Molecular alterations in the nm23 gene have been identified in neur~blastoma.~' It would be of interest to examine whether a similar alteration is present in leukemia.
Several studies suggest that AML-M5 carries a less favorable prognosis because of the shorter duration of response and its association with poor-prognosis factors. When compared with other FAB subtypes of AML, M5 morphology is significantly associated with relapse after conventional therapy andor BM tran~plantation.'~ Hyperleukocytosis is highly frequent in AML-M5, and is associated with prognosis and central nervous system (CNS) involvement. The expression of nm23-HI and -H2 may be a useful indicator of the therapy response and prognosis of AML-M5. We presented data from de novo AML patients and we also analyzed nm23 expression in a patient with secondary AML which had probably been induced by the etoposide used for intensive chemotherapy against malignant lymphoma, and which exhibited chromosomal abnormality inv(l1) (p15;q23). The expression levels of the nm23-HI gene were high in this patient (nm23-HI index = 159 2 0.4), and he died 22 days after diagnosis. On the other hand, 3 AML-M2 patients with t(8;21) expressed lower nm23-HI mRNA levels than the other 3 AML-M2 patients without t(8;21) (P < .01, data not shown). AML-M3 patients with t( 15; 17) also expressed lower nm23-HI mRNA levels than the others (data not shown). Some chromosomal aberrations, such as the t(8;21) and t(15;17), are associated with relatively high rates of remission induction and prolonged remission. These results suggested that elevated levels of nm23-HI mRNA will be useful as an indicator of poor prognosis for other subtypes of AML.
